Over the last 2 years, EVLV has beaten EPS estimates 38% of the time and has beaten revenue estimates 88% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward.

Clinical research company IQVIA (NYSE: IQV) reported Q1 CY2025 results , with sales up 2.5% year on year to $3.83 billion.